The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project
Abstract
Background: Opioid use in patients with renal impairment can lead to increased adverse effects. Opioids differ in their effect in renal impairment in both efficacy and tolerability. This systematic literature review forms the basis of guidelines for opioid use in renal impairment and cancer pain as part of the European Palliative Care Research Collaborative’s opioid guidelines project. Objective: The objective of this study was to identify and assess the quality of evidence for the safe and effective use of opioids for the relief of cancer pain in patients with renal impairment and to produce guidelines. Search strategy: The Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, MedLine, EMBASE and CINAHL were systematically searched in addition to hand searching of relevant journals. Selection criteria: Studies were included if they reported a clinical outcome relevant to the use of selected opioids in cancer-related pain and renal impairment. The selected opioids were morphine, diamorphine, codeine, dextropropoxyphene, dihydrocodeine, oxycodone, hydromorphone, buprenorphine, tramadol, alfentanil, fentanyl, sufentanil, remifentanil, pethidine and methadone. No direct comparator was required for inclusion. Studies assessing the long-term efficacy of opioids during dialysis were excluded. Data collection and analysis: This is a narrative systematic review and no meta-analysis was performed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the quality of the studies and to formulate guidelines. Main results: Fifteen original articles were identified. Eight prospective and seven retrospective clinical studies were identified but no randomized controlled trials. No results were found for diamorphine, codeine, dihydrocodeine, buprenorphine, tramadol, dextropropoxyphene, methadone or remifentanil. Conclusions: All of the studies identified have a significant risk of bias inherent in the study methodology and there is additional significant risk of publication bias. Overall evidence is of very low quality. The direct clinical evidence in cancer-related pain and renal impairment is insufficient to allow formulation of guidelines but is suggestive of significant differences in risk between opioids. Recommendations: Recommendations regarding opioid use in renal impairment and cancer pain are made on the basis of pharmacokinetic data, extrapolation from non-cancer pain studies and from clinical experience. The risk of opioid use in renal impairment is stratified according to the activity of opioid metabolites, potential for accumulation and reports of successful or harmful use. Fentanyl, alfentanil and methadone are identified, with caveats, as the least likely to cause harm when used appropriately. Morphine may be associated with toxicity in patients with renal impairment. Unwanted side effects with morphine may be satisfactorily dealt with by either increasing the dosing interval or reducing the 24 hour dose or by switching to an alternative opioid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence based medicine: what it is and what it isn't
Sackett, D. L., Rosenberg, W. M. C., Gray, J. A. M., Haynes, R. B., & Richardson, W. S. (1996) · BMJ · doi:10.1136/bmj.312.7023.71 · Cited by 15,769
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Atkins, D., Eccles, M., Flottorp, S., Guyatt, G. H., Henry, D., Hill, S., Liberati, A., O'Connell, D., Oxman, A. D., Phillips, B., et al. (2004) · BMC Health Services Research · doi:10.1186/1472-6963-4-38 · Cited by 1,235 · cited 1×
“The assessment of the quality of included papers and subsequent guideline formation was undertaken using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.(8,9) This method balances the intrinsic strengths and weaknesses of the study methodology with any study limitations, and the…”
Method
Cited by
Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70040-2 · Cited by 1,243
Self-citationManagement of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
ASIPP, A. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/s67 · Cited by 386
Trends in Tramadol: Pharmacology, Metabolism, and Misuse
Miotto, K., Cho, A. K., Khalil, M. A., Blanco, K., Sasaki, J. D., & Rawson, R. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001683 · Cited by 354
Management of cancer pain: ESMO Clinical Practice Guidelines
Ripamonti, C. I., Santini, D., Maranzano, E., Berti, M., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds233 · Cited by 329
Metadata
- Authors
- King, S., Forbes, K., Hanks, G., Ferro, C., & Chambers, E.
- Venue
- Palliative Medicine
- Publisher
- SAGE Publications
- Published
- 2011-06-27
- Volume
- 25
- Issue
- 5
- Pages
- 525-552
- ISSN
- 0269-2163 (ISSN-L)
- 1477-030X
- OpenAlex
- W2072680902
- Cited by
- 203
- References
- 3
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. https://app.cochat.ai/papers/10.1177/0269216311406313
- The paper
- King, S., Forbes, K., Hanks, G., Ferro, C., & Chambers, E. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. Palliative Medicine. https://doi.org/10.1177/0269216311406313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.